EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Identification of a glia‐associated amyloid β oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU‐9

Daniel L Kranz iD, Omar de Leon Velez, Emel Ulupinar, P Hande Ozdinler, Richard B Silverman, William L Klein

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Daniel L Kranz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Northwestern University, Evanston, Illinois, USA. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Gliosis, Alzheimer Disease, Neuroglia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, Foundation for the National Institutes of Health, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Neuronal degeneration and immune cell activation occur early in Alzheimer's disease (AD), but the responsible molecules remain undetermined. While exogenous amyloid beta oligomers (AβOs) induce neuronal death and gliosis, the role of endogenous AβOs is less defined. METHODS Brain sections from 1‐ to 12‐month‐old 5xFAD mice were immunolabeled for AβOs, activated glia, phosphorylated transactive response DNA‐binding protein 43 kDa (pTDP‐43), and other AD markers. Neuropathology was analyzed following 60‐day oral treatment with NU‐9, a small‐molecule AβO inhibitor. RESULTS By 8 weeks, AβOs accumulated in the subiculum alongside early reactive astrocytes and activated microglia. Clinical‐stage antibody ACU193 detected AβOs in early‐stage degenerating neurons, while NU4‐labeled denser deposits in late‐stage degenerating neurons. ACU193 + AβOs accumulated on reactive astrocyte surfaces, which also contained pTDP‐43, and later emerged inside activated microglia. NU‐9 reduced astrocyte‐associated ACU193 + AβOs, pTDP‐43, and markedly diminished glial fibrillary acidic protein. DISCUSSION These findings demonstrate in vivo efficacy of NU‐9 and support targeting ACU193 + AβOs to mitigate AD progression. Highlights ACU193 + AβOs accumulated as puncta in neurons at an early stage of degeneration, while NU4 + AβOs appeared as dense deposits only in late‐stage degenerating neurons. The onset and progression of ACU193 + AβOs paralleled activated microglia and reactive astrocytes. ACU193 + AβOs significantly increased on reactive astrocyte surfaces, as NU4 + AβOs accumulated in halos around Thio‐S + plaque cores. In older mice, the ACU193 signal decreased on astrocytes and was found inside activated microglia. Sixty‐day oral NU‐9 treatment significantly reduced astrocyte ACU193 + AβOs and markedly decreased reactive astrogliosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesGliosisAlzheimer DiseaseNeurogliaAnimalsMiceMice, TransgenicAstrocytesDisease Models, AnimalMicrogliaBrainHumansNeurons

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid beta oligomersglial fibrillary acidic proteingliosisphosphorylated transactive response DNA‐binding protein 43 kDa (pTDP‐43)reactive astrocytes

Substanzen

Amyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Neurobiology, Northwestern University, Evanston, Illinois, USA.
  • Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois, USA.
  • Department of Chemistry, Northwestern University, Evanston, Illinois, USA.
  • Department of Molecular Biosciences, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois, USA.
  • Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Daniel L Kranz

Förderung

  • NIA NIH HHS
  • Foundation for the National Institutes of Health
  • NIH
  • National Institutes of Health

Zitieren

APA

Kranz, D. L., de Leon Velez, O., Ulupinar, E., Ozdinler, P. H., Silverman, R. B., & Klein, W. L. (2025). Identification of a glia‐associated amyloid β oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU‐9. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70968

Vancouver

Kranz DL, de Leon Velez O, Ulupinar E, Ozdinler PH, Silverman RB, Klein WL. Identification of a glia‐associated amyloid β oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU‐9. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70968

BibTeX
@article{Kranz2025,
  author = {Kranz, Daniel L and de Leon Velez, Omar and Ulupinar, Emel and Ozdinler, P Hande and Silverman, Richard B and Klein, William L},
  title = {Identification of a glia‐associated amyloid β oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU‐9},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70968}
}
Kostenlos starten →